Soizic Garaud – UBO – SEA EU Talent – Human Health

Title:  Predictive biomarkers of immunotherapy side effects


Recent advances in the treatment of cancer using immunotherapy have dramatically changed patient morbidity and mortality rates. Immune checkpoint inhibitors, alone or combined with other drugs, are currently used both as standard of care or in experimental settings for various cancers to block negative immune regulatory pathways and thereby reinvigorate anti-tumor immunity. Although these drugs have significantly improved the prognosis of many cancer patients, this release also provokes immune-related adverse events (irAE), which can lead to autoimmune-like events affecting multiple organs that present with a wide spectrum of clinical manifestations, ranging from mild to fatal forms, and most commonly affecting the skin, gastrointestinal tract, liver, and endocrine glands. Presently, the specific immune mechanisms driving irAE are unknown and predictive biomarkers are urgently needed. The aim of this project is to decipher the peripheral and tissular immune response to identify predictive biomarkers of irAE.

Soizic Garaud short CV:


The goal of my research is to understand the immune mechanisms of immunotherapy side effects in cancer patients. I focus on the immune profile of lymphocytes in the peripheral blood and within the tissue microenvironment. A better understanding of the pathophysiology leading to side effects may thus lead to the development of predictive biomarkers and a better patient treatment. My skills are cell culture, cellular and molecular biology, proteomics and tissue imaging. 


2009 (Dec.): Doctorate in life sciences and health, Ecole doctorale SICMA, Université de Brest, Brest, France, “honors and distinction”.

2006: Masters Degree of Biology, specializing Genomic and Health, Université Rennes 1, Rennes, France.

2004: Biology degree, specializing in Cellular and Physiological Biology, Université Rennes 1, Rennes, France.

2003: Biology and Biochemistry Analysis degree, specializing in Biology, Institut Universitaire de Technologie, Quimper, France


2022-present: Post-doctoral fellow, LBAI INSERM U1227, Université de Bretagne Occidentale, Brest, France. Head of unit: Pr. Divi Cornec.

2010-2021: Post-doctoral fellow, Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Head of unit: Dr. Karen Willard-Gallo.

2008: International work experience in the Bone and Joint Research Unit (4 months), William Harvey Institute, Queen Mary II University, London, United Kingdom. Head of unit: Prof. R Mageed.

2006-2009: Ph.D. student, Immunologie et Pathologie, CHU Morvan, Brest, France. Head of unit: Prof. P Youinou.


2022-2024: BIENVENUE programme co-funded by the European MSCA-COFUND programme and the regional council of Brittany funding my post-doctoral fellowship (Grant agreement No 899546), “Immunological variables associated to immune checkpoint inhibitor toxicity in cancer patients”.

2010: PhD thesis prize of the European University of Brittany (University of Rennes 1, University of Rennes 2, University of South Brittany and University of West Brittany), France.

2009: Nomination to Young Researchers, at the medical school and Brest hospital, Brest, France.

2008: Mobility grant from European University of Brittany for an International work experience in the Bone and Joint Research Unit (William Harvey Institute, Queen Mary II University, London, UK), France.


  1. Garaud S, Dieu-Nosjean MC, Willard-Gallo K. T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy. Nat Commun. 2022 Apr 26;13(1):2259.  
  2. Boisson A, Noël G, Saiselet M, Rodrigues-Vitória J, Thomas N, Langouo Fontsa M, Sofronii D, Naveaux C, Duvillier H, Craciun L, Larsimont D, Awada A, Detours V, Willard-Gallo K, Garaud S. Detailed characterization of the tumor immune microenvironment by combining multiplex immunohistochemistry with other state of the art approaches. Front Mol Biosci. 2021 Sep 21;8:673042.
  3. Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 2019 Aug 13;5. pii: 129641. 
  4. Garaud S, Zayakin P, Buisseret L, Rulle U, Siliņa K, de Wind A, Van den Eyden G, Larsimont D, Willard-Gallo K, Linē A. Antigen specificity and clinical significance of IgG and IgA autoantibodies produced in situ by tumor-infiltrating B cells in breast cancer. Front Immunol. 2018 Nov 20;9:2660. 
  5. Buisseret L*, Desmedt C*, Garaud S*, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K. Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Mod Pathol. 2017 Sep;30(9):1204-1212. 
  6. Buisseret L*, Garaud S*, de Wind A, Van den Eynden G, Boisson A, Solinas C, Gu-Trantien C, Naveaux C, Lodewyckx JN, Duvillier H, Craciun L, Veys I, Larsimont D, Piccart-Gebhart M, Stagg J, Sotiriou C, Willard-Gallo K. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. OncoImmunology. 2016 Dec 14;6(1):e1257452. 
  7. Garaud S, Roufosse F, De Silva P, Gu-Trantien C, Lodewyckx JN, Duvillier H, Dedeurwaerder S, Bizet M, Defrance M, Fuks F, Bex F, Willard-Gallo K. FOXP1 is a regulator of quiescence in healthy human CD4+ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders. Eur J Immunol. 2017 Jan;47(1):168-179.
  8. Garaud S, Taher TE, Debant M, Burgos M, Melayah S, Berthou C, Parikh K, Pers JO, Luque-Paz D, Chiocchia G, Peppelenbosch M, Isenberg DA, Youinou P, Mignen O, Renaudineau Y, Mageed RA. CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. Cell Mol Immunol. 2016 Aug 8. 42.
  9. Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers JO, Berthou C, Mageed RA, Renaudineau Y, Youinou P. CD5 promotes IL-10 in chronic lymphocytic leukemia B cells production through STAT3 and NFAT2 activation. J Immunol. 2011, 186(8):4835-44.
  10. Garaud S, Le Dantec C, Jousse-Joulin S, Hanrotel-Saliou C, Saraux A, Mageed RA, Youinou P, Renaudineau Y. IL-6 modulates the expression of CD5 in lupus B cells by regulating DNA methylation. J Immunol. 2009,182,5623-5632. 

* These authors contributed equally to this study.


Total number of publications: 42

Total number of citations: 2062

H-index: 22

Source of the bibliometric data: Scopus